Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal OsteoporosisJeanine Flanigan, GH Lyman, Fatemeh Mirzayeh Fashami et al.|PharmacoEconomics - Open|2026Cited by 1